Medical Devices
Health
Medical

Edwards Lifesciences

$188.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$3.16 (-1.64%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell EW and other stocks, options, ETFs, and crypto commission-free!

About

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. Read More The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Critical Care portfolio products hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA..

Employees
12,800
Headquarters
Irvine, California
Founded
1958
Market Cap
39.25B
Price-Earnings Ratio
56.07
Dividend Yield
0.00
Average Volume
1.44M
High Today
$192.93
Low Today
$188.59
Open Price
$192.35
Volume
337.12K
52 Week High
$197.86
52 Week Low
$123.00

Collections

Medical Devices
Health
Medical
Manufacturing
Therapy
Technology

News

Yahoo FinanceMar 21

Edwards Lifesciences Presents Positive Partner 3 Trial Data

The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April. Edwards Lifesciences Corporation EW recently announced favorable randomized PARTNER 3 trial results. The data showed the effectiveness of the SAPIEN 3 transcatheter aortic valve over surgery. The SAPIEN 3 valve has been approved by the FDA for treating intermediate and higher risk patients with severe, symptomatic aortic ...

67
Simply Wall StMar 20

How Much Of Edwards Lifesciences Corporation (NYSE:EW) Do Institutions Own?

A look at the shareholders of Edwards Lifesciences Corporation (NYSE:EW) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. Companies that used to be publicly owned tend to have lower insider ownership. Edwards Lifesciences is a pretty big company. It has a market capitalization of US$39b. Normally institutions would own a significant portion of a company this size. Taking a look ...

29
Yahoo FinanceMar 19

3 High-Performing Large-Cap Stocks

- By Alberto Abaterusso These large-cap companies have exhibited impressive performances on the stock market over the past week, month, year and three years. These companies are expected to continue to do so as analysts forecast a huge upside in their earnings annual growth rate over the next five years. In addition, these stocks received very high ratings from GuruFocus for financial strength as well as profitability and growth. Edwards Lifesciences Corp. (EW) has gained 9% over the last week, ...

0

Earnings

$0.84
$0.97
$1.11
$1.24
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 23, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.